Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|ER-positive Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: AI+CDK4/6i|DRUG: SERD+CDK4/6i|DRUG: mTOR inhibitor + AI|DRUG: mTOR inhibitor + SERD|DRUG: mTOR inhibitor + Selective estrogen receptor modulator|DRUG: PI3K inhibitor + SERD|DRUG: PI3K inhibitor + AI|DRUG: Chemotherapy|DRUG: Oral SERD
Sponsor: University of Miami